Co-Diagnostics Inc. has announced that the Australian Patent Office has granted Australian Patent No. AU2022270084A1, covering its novel Co-Dx PCR platform. This is the first patent granted for the new point-of-care testing platform, providing broad protection in Australia for the proprietary system and methods used for nucleic acid detection and analysis. The patent specifically covers the design and operation of the Co-Dx PCR Pro™ instrument and test cups, supporting the platform’s use for high-quality PCR testing outside traditional laboratory environments. The company stated that this milestone strengthens its intellectual property portfolio as it continues to advance its point-of-care PCR platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA53885) on December 29, 2025, and is solely responsible for the information contained therein.